$NRX Pharmaceuticals Inc.(NRXP)$
https://lastfuturist.com/can-zyesami-treatment-reduce-mortality-rates-for-delta/?fbclid=IwAR3NpN3A5FQc2kJXx6AGPYe_eskJTn8K3c4jlTKUzjDfc4LKTjeHhUYhhvk
In the interview, Dr Javitt mentioned FDA wanted them to submit randomized controlled data, on top of their initial open-label data, and PR on Monday and the number we saw today was the randomized controlled data, and it seems very promising.
The slide that Dr Javitt showed with heading of:
“Zyesami demonstrates clear biologic effect in preventing IL-6 “Cytokine Storm” and then the chart showing Zyesami/Aviptadil treated patients were nearly 1,000% better off in IL-6 level than placebo patients really caught the attention of one of the other presenters who had been singing the praises of Regeneron MABs a few minutes earlier. they asked at least twice “Has this been published…where can I see this data”. This news just needs to go out far and wide in a much more publicized PR. NRXP strong!
Comments